Rituximab as Second Line Treatment for ITP

NCT00344149 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia (ITP)

Interventions

DRUG: Rituximab (Mabthera)

Sponsor

Ostfold Hospital Trust

Collaborators

[object Object]
[object Object]